Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigma-1 Receptors Imaging in Fragile X Syndrome
NCT04314856Phase 1Withdrawn
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]-FTC-146 in Fragile X syndrome (FXS) (2 arms). Primary endpoints: Number of concordant readings of regional brain uptake of radiotracer [18F]FTC-146 at Day 7 and Difference in Non-displaceable Binding Potential (BPND) of [18F]FTC-146 at Day 7. Planned start Jan 2021; status: withdrawn.
02
Drugs
[18F]-FTC-146
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT04314856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314856.